Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Jooeun Bae, Ph.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC. Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 Jul; 34(7):1971. PMID: 31949267.
    Citations:    
  2. Hideshima T, Ogiya D, Liu J, Harada T, Kurata K, Bae J, Massefski W, Anderson KC. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways. Leukemia. 2020 Apr 01. PMID: 32238854.
    Citations:    
  3. Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 01; 34(1):210-223. PMID: 31427721.
    Citations:    
  4. Bae J, Samur M, Richardson P, Munshi NC, Anderson KC. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226. PMID: 30872779.
    Citations:    
  5. Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018 12 01; 4(12):e183267. PMID: 30128502.
    Citations: 1     Fields:    
  6. Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, Munshi NC, Anderson KC. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947. PMID: 29487385.
    Citations: 2     Fields:    
  7. Bae J, Keskin DB, Cowens K, Lee AH, Dranoff G, Munshi NC, Anderson KC. Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. J Leuk (Los Angel). 2015 Jun; 3(2). PMID: 27668268.
    Citations: 1     
  8. Bae J, Samur M, Munshi A, Hideshima T, Keskin D, Kimmelman A, Lee AH, Dranoff G, Anderson KC, Munshi NC. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914. PMID: 25941601.
    Citations: 4     
  9. Bae J, Munshi NC, Anderson KC. Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):927-43. PMID: 25212890.
    Citations: 4     Fields:    Translation:Humans
  10. Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71. PMID: 23293352.
    Citations: 15     Fields:    Translation:HumansCells
  11. Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, Munshi NC. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012 Sep 01; 18(17):4850-60. PMID: 22753586.
    Citations: 18     Fields:    Translation:HumansCells
  12. Bae J, Song W, Smith R, Daley J, Tai YT, Anderson KC, Munshi NC. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol. 2012 Jun; 157(6):687-701. PMID: 22533610.
    Citations: 13     Fields:    Translation:HumansCells
  13. Bae J, Tai YT, Anderson KC, Munshi NC. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011 Nov; 155(3):349-61. PMID: 21902685.
    Citations: 10     Fields:    Translation:HumansCells
  14. Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB, Li C, Catley L, Prabhala R, Anderson KC, Munshi NC. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun 15; 178(12):7730-7. PMID: 17548610.
    Citations: 15     Fields:    Translation:HumansCells
  15. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20. PMID: 16357183.
    Citations: 58     Fields:    Translation:HumansCells
  16. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006 Jan 01; 107(1):301-4. PMID: 16150935.
    Citations: 64     Fields:    Translation:HumansCells
  17. Bae J, Martinson JA, Klingemann HG. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin Cancer Res. 2005 Feb 15; 11(4):1629-38. PMID: 15746068.
    Citations: 2     Fields:    Translation:HumansCells
  18. Bae J, Martinson JA, Klingemann HG. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity. Clin Cancer Res. 2004 Oct 15; 10(20):7043-52. PMID: 15501984.
    Citations: 7     Fields:    Translation:HumansCells
  19. Bae J, Martinson JA, Klingemann HG. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. Cell Immunol. 2004 Jan; 227(1):38-50. PMID: 15051513.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bae's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (98)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.